Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 12Parkinson Disease 4, Autosomal Dominant Lewy Body 8Melanoma 6Carcinoma, Renal Cell 6Neoplasms 5Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Castration-Resistant Prostate Cancer 1

Interventions

pembrolizumab 1lenvatinib 1brivanib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Hepatocellular Carcinoma (HCC) × lenvatinib × Clear all
NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Not yet recruiting
116 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡